Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valder R Arruda

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Seminars in Thrombosis and Hemostasis|February 26, 2021
Gene Therapy for Inherited Bleeding DisordersValder R Arruda, Jesse Weber, Benjamin J Samelson-Jones
Blood|October 12, 2017
Novel approaches to hemophilia therapy: successes and challengesValder R Arruda, Bhavya S Doshi, Benjamin J Samelson-Jones
F1000Research|May 18, 2018
Emerging therapies for hemophilia: controversies and unanswered questionsValder R Arruda, Bhavya S Doshi, Benjamin J Samelson-Jones
Current Gene Therapy|November 6, 2007
Emerging role of regulatory T cells in gene transferOu Cao, Christian Furlan-Freguia, Valder R Arruda, et al.
Current Gene Therapy|September 16, 2022
Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene TherapySteven W Pipe, Valder R Arruda, Claudia Lange, et al.
Haematologica|December 14, 2004
Characterization of mild coagulation factor VII deficiency: activity and clearance of the Arg315Trp and Arg315Lys variants in the Cys310-Cys329 loop (c170s)Christian Furlan Freguia, Raffaella Toso, Eleanor S Pollak, et al.
The Journal of Clinical Investigation|April 2, 2004
Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VIIParis Margaritis, Valder R Arruda, Majed Aljamali, et al.
Molecular Therapy. Methods & Clinical Development|June 4, 2020
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman PrimatesBenjamin J Samelson-Jones, Jonathan D Finn, Patricia Favaro, et al.
Blood|November 20, 2004
Factor IX variants improve gene therapy efficacy for hemophilia BJoerg Schuettrumpf, Roland W Herzog, Alexander Schlachterman, et al.
JCI Insight|June 21, 2019
Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activityBenjamin J Samelson-Jones, Jonathan D Finn, Lindsey A George, et al.
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Seminars in Thrombosis and Hemostasis|February 26, 2021
Gene Therapy for Inherited Bleeding DisordersValder R Arruda, Jesse Weber, Benjamin J Samelson-Jones
Blood|October 12, 2017
Novel approaches to hemophilia therapy: successes and challengesValder R Arruda, Bhavya S Doshi, Benjamin J Samelson-Jones
F1000Research|May 18, 2018
Emerging therapies for hemophilia: controversies and unanswered questionsValder R Arruda, Bhavya S Doshi, Benjamin J Samelson-Jones
Current Gene Therapy|November 6, 2007
Emerging role of regulatory T cells in gene transferOu Cao, Christian Furlan-Freguia, Valder R Arruda, et al.
Current Gene Therapy|September 16, 2022
Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene TherapySteven W Pipe, Valder R Arruda, Claudia Lange, et al.
Haematologica|December 14, 2004
Characterization of mild coagulation factor VII deficiency: activity and clearance of the Arg315Trp and Arg315Lys variants in the Cys310-Cys329 loop (c170s)Christian Furlan Freguia, Raffaella Toso, Eleanor S Pollak, et al.
The Journal of Clinical Investigation|April 2, 2004
Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VIIParis Margaritis, Valder R Arruda, Majed Aljamali, et al.
Molecular Therapy. Methods & Clinical Development|June 4, 2020
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman PrimatesBenjamin J Samelson-Jones, Jonathan D Finn, Patricia Favaro, et al.
Blood|November 20, 2004
Factor IX variants improve gene therapy efficacy for hemophilia BJoerg Schuettrumpf, Roland W Herzog, Alexander Schlachterman, et al.
JCI Insight|June 21, 2019
Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activityBenjamin J Samelson-Jones, Jonathan D Finn, Lindsey A George, et al.
Pageof 9